Injectable Drug Delivery Market

In this webinar we invite the industry’s leading players to join us virtually and examine the latest developments, discuss what major trends are occurring across the industry, share insights and showcase their products and technologies.

  • Virtual Event
  • Complimentary

Why attend?

As one of the widely used conventional drug delivery system, the injectable drug delivery technology market is expected to show significant growth in the coming years, due to various technological advancements and new product launches in order to improve the convenience and ease of administration of parenteral therapeutics. The global injectables market is anticipated to rise at a CAGR of 12.9% to reach USD 1,251.28 billion by the end of 2027. 

Some of the major factors responsible for the growth of this market are the increasing use of biologics, increase in the prevalence of chronic diseases, and the benefits of injections. Injectable drug delivery helps to provide effective and speedy drug administration experience and is considered as one of the most efficient routes of delivery, thus ensuring improved patient experience.  

In this webinar we invite the industry’s leading players to join us virtually and examine the latest developments, discuss what major trends are occurring across the industry, share insights  and showcase their products and technologies.  

Headline Partner

Associate Sponsor



Select a speaker to learn more

Professor Ryan F. Donnelly
Chair in Pharmaceutical Technology, School of Pharmacy, Queen's University Belfast, Medical Biology Centre

Professor Ryan Donnelly holds the Chair in Pharmaceutical Technology at Queen’s University Belfast and is Director of QUB’s new £3 million interdisciplinary research programme Materials & Advanced Technologies for Healthcare (MATCH), comprising 58 academics from Pharmacy, Chemistry & Chemical Engineering, Mechanical & Aerospace Engineering, Biological Sciences, Nursing and Medicine. His personal research is centred on design and physicochemical characterisation of advanced polymeric drug delivery systems for transdermal and intradermal drug delivery, with a strong emphasis on improving patient outcomes. He is currently developing a range of novel microneedle technologies through independent research, but also in collaboration with several major pharma partners. He has obtained substantial (>£10M) UK Research Council (e.g. EP/H021647/1, EP/P034063/1, EP/S028919/1), charity and industrial funding and authored over 600 peer-reviewed publications (H-index = 56; >11,200 citations), including 6 patent applications, 6 textbooks, 26 book chapters and approximately 230 full papers. He has been an invited speaker at numerous national and international conferences. Professor Donnelly is Europe/Africa Editor of Drug Delivery & Translational Research. He has won the Academy of Pharmaceutical Science’s Innovative Science Award (2020), Evonik’s Resomer Award (2018), the Controlled Release Society’s Young Investigator Award (2016), BBSRC Innovator of the Year and the American Association of Pharmaceutical Scientists Pharmaceutical Research Meritorious Manuscript Award (2013), the GSK Emerging Scientist Award (2012) and the Royal Pharmaceutical Society’s Science Award (2011). In addition to leading MATCH and a personal research group of >30 people in his own institution, Professor Donnelly also co-leads MAPs for PreP, a $9.4 million USAID project also including partners from PATH, the Population Council, LTS Lohmann and ViiV Healthcare and MAPs for Peds, a new $4.7 million US NIH project with partners from PATH, ViiV, Janssen and the University of Liverpool.

Next speaker
Nathan Dormer
Director of Drug Product Development, Adare Pharma Solutions

Nathan Dormer, Ph.D. is the Director of Drug Product Development at Adare Pharma Solutions in Lenexa, KS. Dr. Dormer is a pharmaceutical scientist and bioengineer with over a decade of experience developing microsphere-based solid oral and parenteral/implantable dosage forms, with an emphasis on controlled release and other innovative formulation concepts. He is responsible for pharmaceutical development activities such as creation of prototypes, analytical method development, CMC and IP documentation, pharmacokinetic correlations, tech transfer, manufacture of clinical supplies, and commercial scale process optimization and validation. Dr. Dormer received his B.S. in Chemical Engineering and his Ph.D. with Honors in Bioengineering, both from The University of Kansas.

Next speaker
Peter Shapiro
Senior Director of Drugs and Business Fundamentals, GlobalData Plc

Peter Shapiro, PhD, is Senior Director of the Drugs and Business Fundamentals and also serves as the Editor-in-Chief of PharmSource. Peter previously worked on integration of BioPharm Insight, Lead Sheet, and PharmSource into GlobalData’s Pharma Intelligence Center. Prior to joining GlobalData, Peter was an Assistant Manager at Target Health, a Contract Research Organization (CRO) where he helped a diverse set of clients with the demands of bringing biologics, devices, and drugs to the market successfully. Peter also worked in small molecule drug development for Abbvie (then Abbott Labs) and on in vitro diagnostics at Ambergen, a diagnostic startup. Peter holds a PhD in Molecular and Cellular Biology from the Vilcek Institute of New York University and is located in GlobalData’s office in New York City.

Peter is a thought leader in Contract Pharmaceutical manufacturing and has presented on the subject at CPhI North America, CPhI WorldWide, New Statesman Conferences, Arena Clinical Trials Supply, and Arena Clinical Trials Packaging. Peter has an interest in life Science startups. He has volunteer as a guest lecturer, mentor and reviewer for the Bio & Health Tech Entrepreneurship Lab NYC launched by the New York City Economic Development Corporation for the last eight years. He has recently done the same for Accelerator for Biosciences in Connecticut and the Westchester County Biosciences Accelerator.

Next speaker
Dr. Sebastian Braun
Director - Head of Formulation Development and Head of Manufacturing for Innovative Injection Systems, LTS Lohmann Therapie-Systeme AG

Dr Sebastian Braun has worked in the field of transdermal and dermal drug delivery for 15 years at different companies. A molecular biologist by training with a PhD in analytical chemistry and molecular biology, he started his career at a transdermal drug delivery company with a fundamental understanding of the biological workings of the skin. Having spent the last 15 years at different transdermal and dermal drug delivery companies in various positions including head of formulation development, head of manufacturing and head of science and technology, he is now focused on microneedle development and manufacturing for innovative injection systems.

Next speaker

Contact us

If you want to become a sponsor, speak at an event or become a partner, leave a message at the "Partner with us" page and we will contact you as soon as possible.